Key to the development of ReveraGen’s lead compound, VBP15, was the recognition that there are sub-properties of glucocorticoids that are associated with either efficacy or side effects.
ReveraGen's expertise in steroid chemistry was used to change the steroid chemistry to optimize for these sub-properties: transactivation (linked to side effects), Learn more >
In the News
September 2013: VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy
A preclinical study led by researchers at Children’s National Medical Center has found that a new oral drug shows early promise for the treatment of Duchenne muscular dystrophy (DMD). The results, published in EMBO Molecular Medicine, show that the drug, VBP15, decreases inflammation and protects Learn more >
At ReveraGen, we are committed to improving the lives of neuromuscular disease patients.
We are a drug development company engaged in the discovery and development of proprietary therapeutic products for neuromuscular and inflammatory diseases. We are pursuing small molecule drug development for selected indications. ReveraGen’s lead compound, VBP15, is a novel anti-inflammatory currently in development for the chronic treatment of Duchenne muscular dystrophy (DMD). Additional indications and second-generation product candidates are in the pipeline.